抗呕吐药5-HT_(3)受体拮抗剂的经皮给药制剂研究进展  

Research Progress of Transdermal Delivery of Anti-Vomiting Drug 5-HT3 Receptor Antagonist

作　　者：张旭 高秀容 王芊入 胡桃敏 蔡琴 吴星星 张涛[1] 徐源 ZHANG Xu;GAO Xiurong;WANG Qianru;HU Taomin;CAI Qin;WU Xingxing;ZHANG Tao;XU Yuan(Chengdu Medical College,Chengdu 610083,China;Chengdu Pidu District People's Hospital,Chengdu,611730 China;Sichuan Dechang County People's Hospital,Liangshan 615000,China)

机构地区：[1]成都医学院,成都610083 [2]成都市郫都区人民医院,成都611730 [3]四川省德昌县人民医院,四川凉山615000

出　　处：《中国药学杂志》2024年第17期1590-1596,共7页Chinese Pharmaceutical Journal

基　　金：成都医学院-成都市郫都区人民医院联合科研基金资助(2021LHPJ-01);成都医学院大学生省级大学生创新创业训练计划项目资助(S202213705078);四川省医学会青年创新科研课题(项目编号S22041);成都医学院研究生创新科研基金项目(项目编号YCX2023-01-40);凉山州科技计划重点研发科研课题(项目编号23ZDYF0069)。

摘　　要：化疗所致恶心呕吐(chemotherapy induced nausea and vomiting,CINV)是肿瘤患者化疗过程中最常见的不良反应。5-HT_(3)受体拮抗剂类药物被推荐为抗CINV的一线用药。但5-HT_(3)受体拮抗剂药物目前临床常用剂型以口服和静脉给药为主,其中静脉注射给药易产生不良反应且需要专业医护操作,口服给药有首过效应,尤其是化疗后严重呕吐患者无法口服用药,所以目前临床常用剂型具有一定的缺陷,临床应用受到限制。经皮给药系统具有避免胃肠道首过效应、毒副作用小、病人依从性好等优点,所以抗肿瘤所致恶心呕吐药物的经皮给药系统受到人们的广泛关注和研究。本研究就5-HT_(3)受体拮抗剂类药物的经皮给药制剂国内外研究现状进行综述,为该类药物的新制剂和新给药途径研发提供借鉴和参考。Chemotherapy induced nausea and vomiting(CINV)is the most common adverse reaction in cancer patients during chemotherapy.5-HT_(3)receptor antagonists are recommended as the first-line drugs against CINV.However,the commonly used clinical dosage forms of 5-HT_(3)receptor antagonists are mainly oral and intravenous administration,among which intravenous administration is easy to produce adverse reactions and requires professional medical operation.Oral administration has first-pass effect,especially for patients with severe vomiting after chemotherapy,so the commonly used clinical dosage forms have certain defects and limited clinical application.Transdermal drug delivery system has the advantages of avoiding gastrointestinal first-pass effect,less toxic and side effects,and good patient compliance,so the transdermal drug delivery system of anti-tumor nausea and vomiting drugs has been widely concerned and studied.In this paper,the research status of transdermal delivery of 5-HT_(3)receptor antagonists at home and abroad is reviewed,which provides reference for the research and development of new preparations and new delivery routes of these drugs.

关 键 词：肿瘤化疗 恶心呕吐 5-HT_(3)受体拮抗剂 经皮给药 

分 类 号：R944[医药卫生—药剂学]